Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 225

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 225
---
 results in the commencement of delisting proceedings. However, the Company attended a hearing before
a Nasdaq panel (the “Nasdaq Panel”) on December 17, 2024, at which the Company submitted a plan for regaining compliance.
Notwithstanding that applicable Nasdaq rules provide a 180-day compliance period to regain compliance with the MVPHS Requirement, the
plan submitted by the Company in connection with such hearing, as required by applicable Nasdaq requirements, demonstrated a pathway
to compliance with all applicable deficiencies.

On
January 17, 2025, the Nasdaq Panel granted the Company’s request for an extension of
the deadline for regaining compliance with Nasdaq listing requirements to April 22, 2025
(the “Extended Deadline”), subject to certain conditions (the “Nasdaq Conditions”).
Pursuant to the Nasdaq Conditions, the Company shall demonstrate compliance with the Bid
Price Requirement and apply to transfer its listing to the Nasdaq Capital Market on or prior
to January 22, 2025. The Company is also required to satisfy the $2.5 million stockholders’
equity requirement of the Nasdaq Capital Market (the “Stockholders’ Equity Requirement”)
on or prior to the Extended Deadline, submit certain plans to Nasdaq and make certain disclosures.

The Company intends to apply
to transfer its listing to the Nasdaq Capital Market and expects the proceeds of this offering to contribute materially to the satisfaction
of the Stockholders’ Equity Requirement.

Warrant Issuances

On December 23, 2024, the
Company issued warrants to purchase an aggregate of 84,059 shares of Common Stock, with an exercise price of $5.61 per share, which was
the closing price of the Common Stock on Nasdaq on December 20, 2024, to certain institutional investors as a condition to the exercise
of Preferred Warrants held thereby. On January 6, 2025, the Company issued additional warrants to purchase an aggregate of 163,853 shares
of Common Stock, with an exercise price of $5.82 per share, which was the closing price of the Common Stock on Nasdaq on January 3, 2025,
to an institutional investor as a condition to the exercise of Preferred Warrants held thereby. Such number of shares gives effect to
the Reverse Stock Split.

Reverse Stock Split

At 12:01 a.m. Eastern time
on January 8, 2025, we effected the